Cargando…

Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children

BACKGROUND: Juvenile‐onset Huntington's disease (JOHD) is a rare and particularly devastating form of Huntington's disease (HD) for which clinical diagnosis is challenging and robust outcome measures are lacking. Neurofilament light protein (NfL) in plasma has emerged as a prognostic bioma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Byrne, Lauren M., Schultz, Jordan L., Rodrigues, Filipe B., van der Plas, Ellen, Langbehn, Douglas, Nopoulos, Peggy C., Wild, Edward J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Regular Issue Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308659/ https://www.ncbi.nlm.nih.gov/pubmed/35437792 http://dx.doi.org/10.1002/mds.29027

Ejemplares similares

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis
por: Byrne, Lauren M, et al.
Publicado: (2017)

Associations between neurofilament light chain protein, brain structure and chronic kidney disease
por: van der Plas, Ellen, et al.
Publicado: (2022)

The Neurodevelopmental Hypothesis of Huntington’s Disease
por: van der Plas, Ellen, et al.
Publicado: (2020)

Clinical Outcomes and Selection Criteria for Prodromal Huntington's Disease Trials
por: Langbehn, Douglas R., et al.
Publicado: (2020)

Neurofilament light protein in blood predicts regional atrophy in Huntington disease
por: Johnson, Eileanoir B., et al.
Publicado: (2018)

4472 Plasma Neurofilament Light as a Biomarker for Pediatric Patients with Huntington’s Disease
por: Schultz, Jordan L
Publicado: (2020)

Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial
por: Langbehn, Douglas R., et al.
Publicado: (2022)

Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease
por: Shribman, Samuel, et al.
Publicado: (2020)

Developmental Trajectory of Height, Weight, and BMI in Children and Adolescents at Risk for Huntington’s Disease: Effect of mHTT on Growth
por: Tereshchenko, Alexander, et al.
Publicado: (2020)

Behavioral Deficits in Juvenile Onset Huntington’s Disease
por: Langbehn, Kathleen E., et al.
Publicado: (2020)

TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X‐linked Dystonia‐Parkinsonism
por: Al Ali, Jamal, et al.
Publicado: (2020)

3244 The Autonomic Nervous System as a Potential Therapeutic Target in Huntington Disease
por: Schultz, Jordan L, et al.
Publicado: (2019)

Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease?
por: Niemelä, Valter, et al.
Publicado: (2017)

Autonomic Changes in Juvenile-Onset Huntington’s Disease
por: Schultz, Jordan L., et al.
Publicado: (2020)

Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington’s Disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington’s disease
por: Lowe, Alexander J., et al.
Publicado: (2020)

Behavioral features in child and adolescent huntingtin gene‐mutation carriers
por: Reasoner, Erin E., et al.
Publicado: (2022)

Huntington disease: a single-gene degenerative disorder of the striatum
por: Nopoulos, Peggy C.
Publicado: (2016)

Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice
por: Soylu-Kucharz, Rana, et al.
Publicado: (2017)

CAG Somatic Instability in a Huntington Disease Expansion Carrier Presenting with a Progressive Supranuclear Palsy‐like Phenotype
por: Dewan, Ramita, et al.
Publicado: (2022)

A motor for neurofilaments
por: Dove, Alan W.
Publicado: (2002)

Plasma neurofilament light in Huntington’s disease: A marker for disease onset, but not symptom progression
por: Parkin, Georgia M., et al.
Publicado: (2021)

DMPK mRNA Expression in Human Brain Tissue Throughout the Lifespan
por: Langbehn, Kathleen E., et al.
Publicado: (2020)

The relationship between lifestyle and serum neurofilament light protein in Huntington’s disease
por: Cruickshank, Travis, et al.
Publicado: (2020)

Neurofilament Light Chain Is a Novel Biomarker for Major Depression and Related Executive Dysfunction
por: Chen, Mu-Hong, et al.
Publicado: (2021)

Early Changes in Striatal Activity and Motor Kinematics in a Huntington's Disease Mouse Model
por: Koch, Ellen T., et al.
Publicado: (2022)

Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease
por: Rodrigues, Filipe B., et al.
Publicado: (2021)

Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington’s disease
por: Lowe, Alexander J, et al.
Publicado: (2022)

Early Pediatric Chronic Kidney Disease is Associated with Brain Volumetric Gray Matter Abnormalities
por: Solomon, Matthew, et al.
Publicado: (2020)

The Association between CAG Repeat Length and Age of Onset of Juvenile-Onset Huntington’s Disease
por: Schultz, Jordan L., et al.
Publicado: (2020)

Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington’s Disease Patients
por: Szejko, Natalia, et al.
Publicado: (2018)

Psychogenic non-epileptic seizures in early Huntington's disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Huntington’s Disease Clinical Trials Corner: February 2018
por: Rodrigues, Filipe B., et al.
Publicado: (2018)

Huntington’s Disease Clinical Trials Corner: August 2018
por: Rodrigues, Filipe B., et al.
Publicado: (2018)

Hypertension, Antihypertensive Use and the Delayed‐Onset of Huntington's Disease
por: Steventon, Jessica J., et al.
Publicado: (2020)

Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease
por: Byrne, Lauren M., et al.
Publicado: (2018)

Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease
por: Ou, Zhen-Yi Andy, et al.
Publicado: (2021)

Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington's Disease
por: Stoker, Thomas B., et al.
Publicado: (2020)

Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease
por: Niemela, Valter, et al.
Publicado: (2020)

A Critical Review of White Matter Changes in Huntington’s Disease
por: Casella, Chiara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_le2jg733c4pfre6joj25fp9in5